Floxuridine

Floxuridine
Systematic (IUPAC) name
5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a682006
Pregnancy
category
  • (US): D
Routes of
administration
Intra-arterial
Identifiers
CAS Number 50-91-9 YesY
ATC code none
PubChem CID 5790
IUPHAR/BPS 4801
DrugBank DB00322 YesY
ChemSpider 5586 YesY
UNII 039LU44I5M YesY
KEGG D04197 YesY
ChEBI CHEBI:60761 YesY
ChEMBL CHEMBL917 YesY
Chemical data
Formula C9H11FN2O5
Molar mass 246.192 g/mol
  (verify)

Floxuridine (also 5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.

Pharmacology

Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.

Mechanism of action

Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.

History

Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma.

Suppliers

In the US the drug is supplied by APP Pharmaceuticals, LLC; Hospira, Inc.; and Bedford Laboratories.

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.